Guangdong Consun Pharmaceutical Group

Consun Pharmaceutical Group is a leading Chinese pharmaceutical company specializing in the research, development, manufacturing, and marketing of modern Traditional Chinese Medicine (TCM) and chemical medicines. The company holds a dominant position in the Chinese nephrology market, primarily driven by its flagship product, Uremic Clearance Granules, which is a standard treatment for chronic kidney disease. Beyond its core strength in kidney health, Consun has established a significant presence in medical imaging, producing a range of contrast agents for MRI and CT scans. The group also operates in dermatology, hepatobiliary health, and gynecology through its subsidiary, Yulin Pharmaceutical. Listed on the Hong Kong Stock Exchange, Consun focuses on integrating traditional therapeutic wisdom with modern pharmaceutical standards to address unmet clinical needs.